



NEWS RELEASE

# Evolus to Report Second Quarter Financial Results on July 31, 2024

7/17/2024

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- **Evolus, Inc.** (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website [here](#).

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13747672. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at [www.evolus.com](http://www.evolus.com).

## About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive

distributor in Europe of Estyme<sup>®</sup>, a line of unique dermal fillers currently in late-stage development. Visit us at [www.evolus.com](http://www.evolus.com), and follow us on **LinkedIn**, **X**, **Instagram** or **Facebook**.

Jeuveau<sup>®</sup> and Nuceiva<sup>®</sup>, are registered trademarks and Evolysse<sup>™</sup> is a trademark of Evolus, Inc.

Hi-Pure<sup>™</sup> is a trademark of Daewoong Pharmaceutical Co, Ltd.

Estyme<sup>®</sup> is a trademark of Symatase Aesthetics S.A.S.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: [ir@evolus.com](mailto:ir@evolus.com)

Media:

Email: [media@evolus.com](mailto:media@evolus.com)

Source: Evolus